收藏切换
Development of mRNA vaccines in response to the Public Health Emergency of International Concern
收藏切换
PDF
Qing YE, Chengfeng QIN
Synthetic Biology Journal | 2024, 5(2) : 310 - 320
Less
收藏切换
Synthetic Biology Journal | 2024, 5(2): 310-320
Invited Review
Development of mRNA vaccines in response to the Public Health Emergency of International Concern
Full
Qing YE, Chengfeng QIN
Affiliations
  • State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100071,China
Published: 2024-04-30 doi: 10.12211/2096-8280.2023-072
Outline
收藏切换

A Public Health Emergency of International Concern (PHEIC) is defined by the World Health Organization (WHO) as “an extraordinary event which is determined to constitute a public health risk to other states through the international spread of disease and potentially requires a coordinated international response”. To date, WHO has declared seven PHEIC events, including the H1N1 influenza, Ebola, poliomyelitis, Zika, COVID-19 and mpox. Vaccination remains as an effective method in preventing infectious diseases. The International Health Regulations (IHR) Emergency Committee's recommendations for preventing or reducing the international spread of disease and avoiding unnecessary interference with international traffic include an emphases on the development of diagnostics and therapeutics for diseases, as well as the vaccine development. The mRNA vaccine represents a platform technology for the development of next-generation vaccines, and possesses distinct advantages, such as a shortened development cycle, scalable and cost-effective production, as well as enhanced amplification capacity, highlighting its potential in rapid responding to emerging and re-emerging infectious diseases. In recent decades, the development of mRNA synthesis technology and nucleic acid delivery system has facilitated the rapid development of mRNA vaccines and their clinical applications. Here, we overview the development of mRNA vaccines in response to the past PHEICs, and discuss challenges and trends in this regard. Currently, COVID-19 mRNA vaccines have been authorized for human use, while multiple mRNA vaccines against influenza, Zika, mpox and Ebola have been evaluated in clinical or pre-clinical studies. Despite their proven efficacy, there is still room for further improvement of the mRNA vaccines. The mRNA design, optimization, delivery, formulation, manufacturing, storage, and transportation can be further improved by integrating synthetic biology, biochemistry, artificial intelligence, and other multidisciplinary technologies. Although the emergence of the next PHEIC cannot be predicted with certainty, we are optimistic that the mRNA vaccine technology will play a pivotal role in preventing pandemics in the future.

public health emergency of international concern (PHEIC)  /  mRNA vaccine  /  viral infectious disease  /  influenza virus  /  Ebola virus  /  poliovirus  /  Zika virus  /  SARS-CoV-2  /  mpox virus
Qing YE, Chengfeng QIN. Development of mRNA vaccines in response to the Public Health Emergency of International Concern[J]. Synthetic Biology Journal, 2024 , 5 (2) : 310 -320 . DOI: 10.12211/2096-8280.2023-072
Year 2024 volume 5 Issue 2
PDF
484
216
Cite this Article
BibTeX
Article Info
doi: 10.12211/2096-8280.2023-072
  • Receive Date:2023-10-07
  • Online Date:2025-07-07
  • Published:2024-04-30
Article Data
Affiliations
History
  • Received:2023-10-07
  • Revised:2024-01-29
Funding
Affiliations
    State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100071,China
References
Share
https://castjournals.cast.org.cn/joweb/hcsw/EN/10.12211/2096-8280.2023-072
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT